1 Min Read
Sept 13 (Reuters) - Roche Holding AG:
* HERCEPTIN® (TRASTUZUMAB) SUBCUTANEOUS (SC) FORMULATION APPROVED IN CANADA FOR TREATMENT OF HER2-POSITIVE BREAST CANCER Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.